MSMona Safizadeh

Mona Safizadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mona Safizadeh has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Ghasem Fakhraie

    Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Reza Zarei

    Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Sasan Moghimi

    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, USA

    3 shared publications
  • Massood Mohammadi

    Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mehdi Mazloumi

    Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania

    2 shared publications
  • Yadollah Eslami

    Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications

Latest Publications

  • Reply to Comment on: “Evaluation of Anterior Segment Parameters in Pseudoexfoliation Disease Using Anterior Segment Optical Coherence Tomography”

    by Massood Mohammadi, Mohammadkarim Johari, Yadollah Eslami, Reza Zarei, Ghasem Fakhraie, Mona Safizadeh, Sasan Moghimi

  • Evaluation of Anterior Segment Parameters in Pseudoexfoliation Disease Using Anterior Segment Optical Coherence Tomography

    by Massood Mohammadi, Mohammadkarim Johari, Yadollah Eslami, Sasan Moghimi, Reza Zarei, Ghasem Fakhraie, Mona Safizadeh


  • Open Access

    Huge Lateral Rectus Solitary Plasmacytoma Causing Shunt Extrusion

    by Nikoo Hamzeh, Mona Safizadeh, Zohreh Nozarian, Hiva Saffar, Seyed Mohsen Rafizadeh

    A 54-year-old man with a history of radiotherapy for right maxillary sinus plasmacytoma 3 years previously was referred to an orbital clinic with progressive proptosis in his right eye. His vision had deteriorated after an initial improvement after phacoemulsification 2 years before. He had undergone shunt implantation and later shunt removal following plate extrusion with the diagnosis of neovascular glaucoma following CRVO. His vision remained at no light perception afterwards, despite a controlled IOP with topical medications. In his CT scan, a large orbital mass was seen with lateral rectus involvement. He underwent deep orbitotomy for tumor resection following worsening of symptoms, and his symptoms were improved afterwards. Pathology report was consistent with plasmacytoma with anaplastic features. After tumor resection, he underwent another course of radiotherapy with complete remission of symptoms afterwards.


  • Automated Evaluation of Parapapillary Choroidal Microvasculature in Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma

    by Masoud Aghsaei Fard, Mona Safizadeh, Amirreza Shaabani, Rahele Kafieh, Sahar Hojati, Marjan Afzali, Yanin Suwan, Robert Ritch, Sasan Moghimi


  • Ahmed glaucoma valve implantation with and without subconjunctival bevacizumab in refractory glaucoma

    by Reza Zarei, Mehrbod Ghasempour, Ghasem Fakhraie, Yahya Eslami, Massood Mohammadi, Nikoo Hamzeh, Fereydun Sajadi, Mona Safizadeh

    Purpose To evaluate the effects of subconjunctival bevacizumab injection on intraocular pressure (IOP), hypertensive phase, and failure and success rates of Ahmed Glaucoma Valve (AGV) implantation. Methods A total of 63 eyes of 63 patients (30 cases in control and 33 cases in bevacizumab group) were included in this randomized masked prospective clinical trial. Pre- and postoperative BCVA, IOP, number of medications, complications and success rates were compared between AGV + bevacizumab and AGV alone group. Results Both groups showed statistically significant reductions in IOP in all their follow-up visits (P < 0.05). The mean IOP was lower in the AGV + Bevacizumab group than AGV group in all follow-up visits. However, the difference was only significant at the 3rd month (17.3 ± 6.2 vs. 20.7 ± 4.6, p = 0.04). The number of medications was not differed significantly between the two groups at their last visit (p value = 0.84) Complete success rate was higher in AGV + Bevacizumab. However, the difference was not significant (p = 0.73). The qualified and overall success rate, failure rate and the need for second tube were not statistically different between the two groups. The hypertensive phase was not statistically significant between the 2 groups (33.3% in AGV + Bevacizumab group and 50% in AGV group, p = 0.06) Conclusion Adjunctive use of Bevacizumab during AGV implantation is beneficial in controlling hypertensive phase and IOP control and may lead to higher success rates and lower failure rates after AGV implantation. However, whether it’s clearly beneficial or its exact role remains to be investigated.


  • Open Access

    Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats

    by Mohammad Nasser Hashemian, Hadi Z. Mahrjerdi, Mehdi Mazloumi, Mona S Safizadeh, Yadollah Shakiba, Firouzeh Rahimi, Mohsen Afarideh, Mohamad Ali Zare, Mohammadreza Fallah Tafti, Bahram Bohrani Sepidan, et al.

    Background: To compare the efficacy of subconjunctival administration of bevacizumab and different doses of sunitinib malate in reducing corneal neovascularization (CNV). Materials and Methods: In this experimental study, central corneal cauterization was created in the right eye of fifty male Sprague–Dawley rats. On day 1 (1 week after cauterization), rats were randomly assigned into five treatment groups. Group control (n = 10) received subconjunctival injection of 0.02 ml of base saline solution. Group 1 (n = 10) received 0.02 ml of bevacizumab (25 mg/ml). Group 2, 3, and 4 (n = 10 for each group) were treated with 0.02 ml of sunitinib malate (10, 20, and 50 μg/ml, respectively). On days 1, 7, and 14, digital photographs of the cornea were taken, and the area of CNV was measured. Results: During the 2-week follow-up, CNV area in treatment groups was less than in control group (P < 0.05). On day 7, corneal avascular area was highest in Group 3 at 63%. On day 14, the area of CNV in Groups 2 and 3 was less than in Group 1 (P = 0.031 and 0.011, respectively), but the difference between Groups 2 and 3 was not statistically significant (P = 0.552). The decreased CNV area on day 14 in Group 4 was significant in comparison to bevacizumab, but it was not significant on day 7 (P = 0.25 on day 7 and 0.002 on day 14). Conclusion: Subconjunctival sunitinib malate is more effective than bevacizumab in regressing CNV. This effect is more prominent on day 14.


  • Evaluation of Corneal Biomechanical Properties in Patients With Thyroid Eye Disease Using Ocular Response Analyzer

    by Sasan Moghimi, Mona Safizadeh, Mehdi Mazloumi, Hamid Hosseini, Zakieh Vahedian, Mohammad T. Rajabi

    To assess variations in the corneal biomechanical properties in thyroid eye disease (TED) patients using ocular response analyzer (ORA). In this observational cross-sectional study, 75 patients with TED and 57 healthy subjects were enrolled. The mean age of the patients and healthy subjects were 47.50±1.55 and 43.6±1.23 years, respectively (P=0.06). All study participants underwent comprehensive ophthalmologic examination, Goldmann applanation tonometry (GAT), corneal pachymetry, and corneal biomechanical analysis using ORA. Corneal hysteresis (CH), corneal resistance factor (CRF), cornea-compensated IOP value (IOPcc), and Goldmann-corrected IOP value (IOPg) were measured with ORA. Central corneal thickness (CCT) in patients group (536.18±36.20 μm) and control group (539.22±28.83 μm) were not significantly different (P=0.1). In TED group, the IOPcc (20.23±0.54 mm Hg) was significantly higher than both IOP-GAT (17.54±0.49 mm Hg, P<0.001) and IOPg (18.35±0.52, P<0.001). CH in TED patients (9.01±0.20) was significantly lower compared with CH in healthy subjects (10.45±0.21) (P<0.001). Although CRF was lower in TED patients (10.06±0.16) in comparison with normal subjects (10.42±0.29), this difference was not statistically significant (P=0.25). Both CH and CRF were positively correlated with CCT (r=0.52, P<0.001 and r=0.62, P<0.001, respectively) in TED group. In TED patients, CH seems to be lower than in normal subjects. GAT might underestimate the IOP due to differences in corneal properties of cornea in TED patients.